Atlas Trials

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer

Clinical trial NCT02973763 · TERMINATED

Trial details

NCT number
NCT02973763
Sponsor
Allist Pharmaceuticals, Inc.
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
NSCLC
Start date
2016-12-30
Primary completion
2021-02-04
Enrollment
14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.